Immune Therapeutics, Inc. filed its 10-K on Apr 10, 2023 for the period ending Dec 31, 2022. In this report its auditor, Turner, Stone & Company, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0598 USD | +19.72% |
|
+43.41% | -18.08% |
May. 20 | Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 16 | Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-18.08% | 5.01M | |
+15.58% | 121B | |
+16.60% | 110B | |
+18.89% | 25.98B | |
-24.33% | 19.27B | |
-18.33% | 15.99B | |
-17.95% | 15.66B | |
-48.32% | 14.5B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- BTAX Stock
- News Biostax Corp.
- Immune Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt